In this way, gene silencing of PLN is known to possess beneficial properties in both PLN r14del as well as general HF, allowing it to be a promising treatment strategy for PLN r14del-associated cardiomyopathy and HF. This evidence concerns the gene PLN and cardiomyopathy.